KDR and neoplasm: Sorafenib, a multikinase inhibitor, has activities against Raf kinase and several receptor tyrosine kinases, such as vascular endothelial growth factor receptor 2, platelet-derived growth factor receptor, FLT3, Ret, and c-Kit, and inhibits tumor angiogenesis in HCC [11].